Background: Imidazolium salts (IS), ionic derivatives of neutral imidazoles, have properties that can be adjusted by structural modifications to their cations and anions, which makes this particular class of compounds a promising option for developing biologically active compounds. The anti-tumor effects of the IS 1-n-butyl-3-methylimidazolium chloride (C MImCl), 1-n-decyl-3-methylimidazolium chloride (C MImCl), 1-n-hexadecyl-3-methylimidazolium chloride (C MImCl), 1-n-hexadecyl-2,3-dimethylimidazolium chloride (C M ImCl), 1-n-octadecyl-3-methylimidazolium chloride (C MImCl), 1-n-hexadecyl-3-methylimidazolium methanesulfonate (C MImMeS), and 1-n-hexadecyl-2,3- dimethylimidazolium methanesulfonate (C M ImMeS) on oral squamous cell carcinoma (OSCC) have been studied here.
Methods: Oral squamous cell carcinoma cells (CAL27) were incubated with increasing IS doses and then submitted to proliferation (2D), cell death (2D) and spheroid assay (3D).